A phase I study of chemoradiotherapy (cisplatin and vinorelbine) with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer
Phase 1
- Conditions
- on-small-cell lung cancer
- Registration Number
- JPRN-UMIN000003769
- Lead Sponsor
- Osaka Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
(1) With interstitial pneuminia or pulmonary fibrosis (2) Presence of other active malignancy (3) Pregnancy or lactating patients (4) A male without the intention to contraception (5) With sever cardiac diseases (6) Un-controlled DM (7) With sever infection (8) With high fiver (9) Previous treatment of thoracic irradiation (10) Others
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method recommended dose of radiotherapy
- Secondary Outcome Measures
Name Time Method Toxicity, response, overall survival